Estatísticas Básicas
| LEI | 549300BG1T7KL678Y212 |
| CIK | 1596812 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enlivex Ltd.
SEC Filings (Chronological Order)
Esta página fornece uma lista completa e cronológica de Arquivamentos da SEC, excluindo os arquivamentos de propriedade que fornecemos em outro lugar.
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) I |
|
| May 28, 2026 |
Exhibit 99.1 Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board ● As of May 27, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.16 billion. ● Separately, the Rain Foundation recently announced the appointment of five industry leaders to its advisory board, supportin |
|
| May 27, 2026 |
Exhibit 99.1 Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity ● Rain, with an additional $100 Million Liquidity Commitment, Currently Anchors Top Three Positioning Among Global Prediction Market Leaders, Following Polymarket, with Approximately $450 million, and Kalshi1. ● Rain’s Upgraded Positio |
|
| May 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) I |
|
| May 18, 2026 |
Exhibit 99.1 Enlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis ● Enrollment milestone follows FDA IND clearance received in March 2026 and Danish Medicines Agency (DKMA) approval received in April 2026 Nes-Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -Enlivex Ltd. (Nasdaq: ENLV) (“ |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) I |
|
| May 15, 2026 |
Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification Exhibit 99.1 Enlivex Announces Receipt of Nasdaq Minimum Bid Price Notification Nes-Ziona, Israel, May 15, 2026 (GLOBE NEWSWIRE) - Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the closing bid price o |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) I |
|
| May 1, 2026 |
23,333,333 Ordinary Shares ENLIVEX LTD. Filed pursuant to Rule 424(b)(3) Registration No. 333-295215 PROSPECTUS 23,333,333 Ordinary Shares ENLIVEX LTD. This prospectus relates to the resale by the selling shareholder named in this prospectus (the “Selling Shareholder”) from time to time of up to an aggregate of 23,333,333 ordinary shares, par value NIS 0.40 per share (the “ordinary shares”), in amounts, at prices and on terms that will |
|
| April 28, 2026 |
Enlivex Ltd. 14 Einstein Street Ness Ziona Israel 7403618 Enlivex Ltd. 14 Einstein Street Ness Ziona Israel 7403618 April 28, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes RE: Enlivex Ltd. (the “Company”) Registration Statement on Form F-3 (the “Registration Statement”) Filed April 21, 2026 File No. 333-295215 Dear Mr. Howes: The Company hereb |
|
| April 27, 2026 |
April 27, 2026 Oren Hershkovitz Chief Executive Officer Enlivex Ltd. 14 Einstein Street Ness Ziona Israel 7403618 Re: Enlivex Ltd. Registration Statement on Form F-3 Filed April 21, 2026 File No. 333-295215 Dear Oren Hershkovitz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We |
|
| April 21, 2026 |
CALCULATION OF FILING FEE TABLES Enlivex Ltd. Table 1: Newly Registered and Carry Forward Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 Enlivex Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, $0.40 p |
|
| April 21, 2026 |
As filed with the Securities and Exchange Commission on April 21, 2026 As filed with the Securities and Exchange Commission on April 21, 2026 Registration No. |
|
| April 21, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) |
|
| April 21, 2026 |
Exhibit 99.1 Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis · Approval by the Danish Medicines Agency (DKMA) for enrolling patients in Denmark follows the recently announced FDA clearance to initiate the Phase 2b study in the United States. Nes-Ziona, Israel, April 21, 2026 — Enlivex Ltd. (Nasdaq: ENLV) (“E |
|
| April 8, 2026 |
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares Exhibit 99.1 Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares Nes-Ziona, Israel, April 08, 2026 (GLOBE NEWSWIRE) - Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that Ondo Finance (“Ondo”) has launched ENLVon, the Ondo tokenized representation of ENLV’s ordinary shares on Ondo’s Global Markets pl |
|
| April 8, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) |
|
| March 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) |
|
| March 26, 2026 |
Exhibit 99.1 Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt · According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers · The Rain Foundation announced a $5 million grant pr |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) |
|
| March 25, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2025 (the “Report”) by Enlivex Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, |
|
| March 25, 2026 |
Exhibit 99.1 Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 - Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financial results and business highlights for the year ended December 31, 2025. Net inco |
|
| March 25, 2026 |
Exhibit 4.3 INDEMNIFICATION AGREEMENT To: This Indemnification Agreement (“Indemnification Agreement”) is being entered into by and between (the “Indemnitee”) and Enlivex Therapeutics Ltd., a company organized under the laws of the state of Israel (the “Company”), effective as of , pursuant to the resolutions of the Board of Directors of the Company (the “Board”), dated , as approved by the Compan |
|
| March 25, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dr. Oren Hershkovitz, certify that: 1. I have reviewed this Annual Report on Form 20-F of Enlivex Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such |
|
| March 25, 2026 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2025 (the “Report”) by Enlivex Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, |
|
| March 25, 2026 |
CONSENT OF INDEPENDENT ACCOUNTANTS Exhibit 15.1 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-252926, File No. 333-286956, File No. 333-292417 and File No. 333-294284) of Enlivex Ltd. of our report dated March 25, 2026 with respect to the consolidated financial statements and th |
|
| March 25, 2026 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Shachar Shlosberger, certify that: 1. I have reviewed this Annual Report on Form 20–F of Enlivex Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such |
|
| March 25, 2026 |
DESCRIPTION OF ORDINARY SHARES Exhibit 2.1 DESCRIPTION OF ORDINARY SHARES As of the end of the period covered by the most recent Annual Report on Form 20-F of Enlivex Ltd. (the “Company”) to which this Exhibit is filed, or incorporated by reference, as an exhibit, the Company’s ordinary shares, with a par value of NIS 0.40 per share (the “ordinary shares”), were registered under Section 12 of the Securities Exchange Act of 1934 |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 24, 2026 |
ENLIVEX LTD. Form of Senior Secured Convertible Promissory Note due March 23, 2027 Exhibit 10.2 Execution Version NEITHER THE ISSUANCE AND SALE OF THIS NOTE NOR THE ORDINARY SHARES ISSUABLE UPON CONVERSION OR REPAYMENT OF THIS NOTE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT B |
|
| March 24, 2026 |
Exhibit 10.3 Execution Version SECURITY AGREEMENT SECURITY AGREEMENT (this “Agreement”), dated as of March 23, 2026, by and between ENLIVEX LTD., a company organized under the laws of the State of Israel (the “Company”) and LIND GLOBAL ASSET MANAGEMENT XIV LLC, a Delaware limited liability company (the “Secured Party”). WHEREAS, the Company (a) and the Secured Party have entered into that certain |
|
| March 24, 2026 |
Exhibit 99.2 The Quality Longevity Company Powered by a Prediction Markets Treasury Forward - looking statements This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amende d, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward - looking statements may be identified by words such as “expects,” “pla |
|
| March 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) |
|
| March 24, 2026 |
Exhibit 99.1 Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program ● $21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor ● The Company exercised an option to acquire a |
|
| March 24, 2026 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (as amended, supplemented, restated and/or modified from time to time, this “Agreement”) is entered into as of March 23, 2026, by and between Enlivex Ltd., a company organized under the laws of the State of Israel (the “Company”), and Lind Global Asset Management XIV LLC, a Delaware limited liability co |
|
| March 24, 2026 |
JOINDER AND FIRST AMENDMENT TO ASSET MANAGEMENT AGREEMENT Exhibit 10.4 Execution Version JOINDER AND FIRST AMENDMENT TO ASSET MANAGEMENT AGREEMENT This JOINDER AND FIRST AMENDMENT TO ASSET MANAGEMENT AGREEMENT, dated as of March 23, 2026 (this “Amendment”), is made by and among Enlivex Ltd., a company organized under the laws of the State of Israel (formerly Enlivex Therapeutics Ltd., the “Company” or the “Client”), Elinnovation Labs Ltd., a company orga |
|
| March 23, 2026 |
Exhibit 99.1 Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis ● Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value cre |
|
| March 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offices) |
|
| March 20, 2026 |
Up to $250,000,000 of Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-286956 Prospectus Supplement (to Prospectus Dated May 12, 2025) Up to $250,000,000 of Ordinary Shares This prospectus supplement updates and amends certain information contained in the prospectus supplement, dated November 24, 2025, and the accompanying prospectus, dated May 12, 2025 (together, the “Prospectus”), relating to the sale of our ord |
|
| March 13, 2026 |
CALCULATION OF FILING FEE TABLES Enlivex Ltd. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Enlivex Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, par value NIS 0.40 per share, to be issued under the Enlivex Therapeutics Ltd. Globa |
|
| March 13, 2026 |
As filed with the Securities and Exchange Commission on March 13, 2026 As filed with the Securities and Exchange Commission on March 13, 2026 Registration No. |
|
| February 23, 2026 |
Exhibit 99.1 CERTIFICATE OF CHANGE OF NAME This is to certify that the company: Company Number: 514716489 Changed its name in Israel according to Companies Laws in the State of Israel, and beginning of 10TH FEBRUARY 2026 it will be called: Shuli Avni-Shoham, Adv. Registrar of Companies Head of the Israeli Corporations Authority PRODUCED ON 10TH FEBRUARY 2026 AT 17:00 To obtain a company informatio |
|
| February 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 Commission file number: 001-36578 ENLIVEX LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executive offic |
|
| February 10, 2026 |
Exhibit 99.1 Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported th |
|
| February 10, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| February 5, 2026 |
Exhibit 99.1 Articles of Association of Enlivex Therapeutics Ltd. A Company Limited by Shares Under The Companies Law, 5759-1999 Chapter 1 General 1 Chapter 2 Shares and Share Capital 2 Chapter 3 General Meetings 5 Chapter 4 The Board of Directors 8 Chapter 5 Committees of the Board of Directors 12 Chapter 6 General Manager 12 Chapter 7 Exemption, Insurance, and Indemnification 13 Chapter 8 Intern |
|
| February 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2026 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| January 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2026 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| January 26, 2026 |
Exhibit 99.1 Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange Listing expected to expand market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today reported that its primary treasury asset, |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2026 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| January 23, 2026 |
Exhibit 99.1 Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing Nes-Ziona, Israel, Jan. 23, 2026 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV) (“Enlivex” or “the Company”), a clinical-stage macrophage reprogra |
|
| January 7, 2026 |
Exhibit 99.1 Enlivex Treasury Portfolio Update: Listing of the RAIN Token on KuCoin, a Leading Cryptocurrency Exchange The listing on one of the world’s largest global cryptocurrency exchanges expands market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, January 7, 2026 - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”) today repo |
|
| January 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2026 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| January 6, 2026 |
212,000,000 Ordinary Shares ENLIVEX THERAPEUTICS LTD. Filed pursuant to Rule 424(b)(3) Registration No. 333-292417 PROSPECTUS 212,000,000 Ordinary Shares ENLIVEX THERAPEUTICS LTD. This prospectus relates to the resale by the selling shareholders named in this prospectus (each, a “Selling Shareholder,” and, collectively, the “Selling Shareholders”) from time to time of up to an aggregate of 212,000,000 ordinary shares, par value NIS 0.40 per share (th |
|
| December 30, 2025 |
Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Israel 7403618 Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Israel 7403618 December 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jimmy McNamara RE: Enlivex Therapeutics Ltd. (the “Company”) Registration Statement on Form F-3 (the “Registration Statement”) Filed December 23, 2025 File No. 333-29241 |
|
| December 29, 2025 |
December 29, 2025 Shachar Shlosberger Chief Financial Officer Enlivex Therapeutics Ltd. |
|
| December 23, 2025 |
Exhibit 4.1 Articles of Association of Enlivex Therapeutics Ltd. A Company Limited by Shares Under The Companies Law, 5759-1999 Chapter 1 General 1 Chapter 2 Shares and Share Capital 2 Chapter 3 General Meetings 6 Chapter 4 The Board of Directors 10 Chapter 5 Committees of the Board of Directors 14 Chapter 6 General Manager 15 Chapter 7 Exemption, Insurance, and Indemnification 15 Chapter 8 Intern |
|
| December 23, 2025 |
As filed with the Securities and Exchange Commission on December 23, 2025 As filed with the Securities and Exchange Commission on December 23, 2025 Registration No. |
|
| December 23, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 Enlivex Therapeutics, Ltd. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary S |
|
| December 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| December 18, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on February 3, 2026 Dear Shareholder: We cordially invite you to attend an Extraordinary General Meeting of Shareholders (the “Meeting”) of Enlivex Therapeutics Ltd. (the “Company”) to be held on Tuesday, February 3, 2026, at 7:00 p.m. (Israel time), at the offices of the Company at 14 Einstei |
|
| December 18, 2025 |
Exhibit 99.2 THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN. EXCEPT AS MENTIONED OTHERWISE IN THE PROXY STATEMENT AND BELOW ON THIS PROXY, IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” THE PROPOSALS HEREIN. Please mark your vote as in this example ☒ PROPOSAL NO. 1: To approve certain amendments to the Company’s Articles of Association, including, among other thin |
|
| December 4, 2025 |
Exhibit 99.1 Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development Nes-Ziona, Israel, December 4, 2025 - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, December 11, 2025 at 11:00 am ET. Shai Novik, Executive Chairman of Enlivex, will prov |
|
| December 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 26, 2025 |
Exhibit 99.1 Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement - Enlivex has adopted the world’s first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentralized predictions and options protocol that redefines predictive market ecosystems and provides a powerful platform for on-chain market creation - b |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 24, 2025 |
Exhibit 99.1 Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announc |
|
| November 24, 2025 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], 2025, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pu |
|
| November 24, 2025 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 24, 2025, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the |
|
| November 24, 2025 |
Exhibit 99.3 RAIN Treasury Strategy PubCo BUILT ON Disclaimer This presentation has been prepared by PubCo (the “Company”) solely for informational purposes in connection with a potential private placement of the Company’s securities. The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the Company and the proposed transact |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 24, 2025 |
Exhibit 99.2 Nasdaq: ENLV ENLIVEX CLINICAL DEVELOPMENT November 2025 FORWARD - LOOKING STATEMENTS 2 | Nasdaq: ENLV These slides and the accompanying oral presentation contain forward - looking statements and information. Forward - looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, perf |
|
| November 24, 2025 |
Exhibit 10.3 ASSET MANAGEMENT AGREEMENT This ASSET MANAGEMENT AGREEMENT (this “Agreement”), effective November 20, 2025 (the “Effective Date”) is made and entered into, by and between: 1. Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company” or the “Client”), with registration number: 514716489, and 2. Elinnovation Labs Ltd., a company organized under |
|
| November 24, 2025 |
Exhibit 10.4 SHAREHOLDERS’ AGREEMENT This SHAREHOLDERS’ AGREEMENT, dated as of [●], 2025 (this “Agreement”), is entered into by and among Enlivex Therapeutics Ltd., a company formed under the laws of the State of Israel (the “Company”), and those shareholders of the Company listed on Exhibit A hereto who have become parties to this Agreement through the execution of a counterpart signature page (t |
|
| November 24, 2025 |
ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.1 ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: – Issue Date: November [●], 2025 THIS ORDINARY SHARE PRE-FUNDED PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the |
|
| November 24, 2025 |
Exhibit 99.2 Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board - Upon the closing of the private placement, Enlivex will adopt the world’s first RAIN prediction markets token digital asset treasury strategy, via |
|
| November 24, 2025 |
Up to $299,553,108 of Ordinary Shares Filed Pursuant to Rule 424(b)(5) Registration No. 333-286956 Prospectus Supplement (to Prospectus Dated May 12, 2025) Up to $299,553,108 of Ordinary Shares On November 24, 2025, we entered into an At-The-Market Sales Agreement (the “Sales Agreement”), with BTIG, LLC (the “Sales Agent”), relating to the sale of our ordinary shares, par value NIS 0.40 per share (“ordinary shares”) covered by this pr |
|
| November 24, 2025 |
ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.2 ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: Issue Date: November [●], 2025 Initial Exercise Date: November [●], 2025 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 24, 2025 |
Exhibit 10.5 Execution Version Enlivex Therapeutics Ltd. Up to $299,553,108 OF Ordinary Shares (par value NIS0.40 per share) At-the-market SALES AGREEMENT November 24, 2025 BTIG, LLC 65 East 55th Street New York, New York 10022 Ladies and Gentlemen: Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with B |
|
| November 24, 2025 |
Exhibit 99.1 November 15, 2025 Risk Disclosure Document This risk disclosure document is being delivered to you in connection with the private placement by Enlivex Therapeutics Ltd., a company formed under the laws of Israel (the “Company”), of its ordinary shares (the “Offering”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in |
|
| November 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 14, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 IND |
|
| November 14, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| November 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| September 25, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on November 10, 2025 Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Enlivex Therapeutics Ltd. (the “Company”) to be held on Monday, November 10, 2025, at 7:00 p.m. (Israel time), at the offices of the Company at 14 Einstein Street, Ne |
|
| September 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 25, 2025 |
Exhibit 99.2 ENLIVEX THERAPEUTICS LTD. C/O COGENCY GLOBAL INC. 122 EAST 42ND STREET, 18TH FLOOR NEW YORK, NY 10168 SCAN TO VIEW MATERIALS & VOTE VOTE BY INTERNET - www.proxyvote.com or scan the QR Barcode above Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11:59 p.m. Eastern Time on November 6, 2025. Have your proxy card in hand when you |
|
| September 11, 2025 |
Exhibit 99.1 Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected November 2025; Phase IIb trial initiation planned for Q2 2026 Nes-Ziona, Israel, |
|
| September 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 9, 2025 |
Exhibit 99.1 Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Nes-Ziona, Israel, September 8, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of an Israeli patent, numbered 290470, titled, “THERAPEUTIC APOPT |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exec |
|
| August 29, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| August 29, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2025 AND 2024 INDEX TO CONDENSED CONSOL |
|
| August 18, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS PHASE IIA TOPLINE RESULTS Aug 2025 These slides and the accompanying oral presentation contain forward - looking statements and information. Forward - looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially diffe |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exec |
|
| August 18, 2025 |
Exhibit 99.1 Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee pain and 26% |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exec |
|
| August 14, 2025 |
Exhibit 99.1 Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, August 14, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exec |
|
| July 28, 2025 |
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data Exhibit 99.1 Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all 134 patients in its Phase II stage of its randomized, controlled, blinded Phase I/II trial of All |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executi |
|
| May 30, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2025 AND DECEMBER 31, 2024 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2025 AND 2024 INDEX TO CONDENSED CONSOLIDATED FINAN |
|
| May 30, 2025 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| May 13, 2025 |
Up to 8,800,000 Ordinary Shares Filed pursuant to Rule 424(b)(3) Registration No. 333-286956 Prospectus Up to 8,800,000 Ordinary Shares On December 30, 2022, we entered into a sales agreement (the “Sales Agreement”), with Cantor Fitzgerald & Co. and Citizens JMP Securities, LLC, as agents (each an “Sales Agent” and together the “Sales Agents”), relating to the sale of our ordinary shares, par value NIS 0.40 per share (“ordinary |
|
| May 8, 2025 |
Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Israel 7403618 Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Israel 7403618 May 8, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Tyler Howes RE: Enlivex Therapeutics Ltd. (the “Company”) Registration Statement on Form F-3 (the “Registration Statement”) Filed May 2, 2025 File No. 333-286956 Dear Mr. Howe |
|
| May 7, 2025 |
May 7, 2025 Oren Hershkovitz Chief Executive Officer Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Israel 7403618 Re: Enlivex Therapeutics Ltd. Registration Statement on Form F-3 Filed May 2, 2025 File No. 333-286956 Dear Oren Hershkovitz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests |
|
| May 2, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) Enlivex Therapeutics, Ltd. |
|
| May 2, 2025 |
As filed with the Securities and Exchange Commission on May 2, 2025 As filed with the Securities and Exchange Commission on May 2, 2025 Registration No. |
|
| April 30, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2024 (the “Report”) by Enlivex Therapeutics Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley |
|
| April 30, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dr. Oren Hershkovitz, certify that: 1. I have reviewed this Annual Report on Form 20-F of Enlivex Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances und |
|
| April 30, 2025 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2024 (the “Report”) by Enlivex Therapeutics Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley |
|
| April 30, 2025 |
CONSENT OF INDEPENDENT ACCOUNTANTS Exhibit 15.1 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-264561) of Enlivex Therapeutics Ltd. of our report dated March 31, 2025 with respect to the consolidated financial statements and the effect |
|
| April 30, 2025 |
Exhibit 11.1 ENLIVEX THERAPEUTICS LTD. INSIDER TRADING POLICY AND GUIDELINES WITH RESPECT TO CERTAIN TRANSACTIONS IN COMPANY SECURITIES Date: June 23, 2015 This Insider Trading Policy (the “Policy”) provides guidelines to directors, officers, employees and other related individuals of Enlivex Therapeutics Ltd, an Israeli company (the “Company”), with respect to transactions in the Company’s securi |
|
| April 30, 2025 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Shachar Shlosberger, certify that: 1. I have reviewed this Annual Report on Form 20–F of Enlivex Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2025 |
THIRD AMENDMENT TO CONSULTING AGREEMENT Exhibit 4.21 THIRD AMENDMENT TO CONSULTING AGREEMENT THIS THIRD AMENDMENT (the “Third Amendment”) is entered into as of November 7, 2024, by and between Enlivex Therapeutics, Ltd., a company organized under the laws of the State of Israel, corporate number 51373620, whose address is at 14 Einstein Street, Ness Ziona, Israel 7403618 (the “Company”) and A.S. Novik Ltd., a company organized under the |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| April 23, 2025 |
Exhibit 99.1 Enlivex Therapeutics to Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress Presentations to underscore AllocetraTM’s novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today a |
|
| April 21, 2025 |
Exhibit 99.1 Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enr |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| April 3, 2025 |
Exhibit 99.1 Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis ● Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally ● TMJ causes pain and stiffness in the jaw, making it diffi |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| March 31, 2025 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-5 Consolidated Statements of Operations and Comprehensive Loss F-6 Consolidated Statements of Changes in Shareholders’ Equity F-7 Consolidated S |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| March 31, 2025 |
CONSENT OF INDEPENDENT ACCOUNTANTS Exhibit 99.2 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-264561) of Enlivex Therapeutics Ltd. of our report dated March 31, 2025 with respect to the consolidated financial statements and the effect |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| March 17, 2025 |
Exhibit 99.1 Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration (CNIP |
|
| March 4, 2025 |
Exhibit 99.1 Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis Ness-Ziona, Israel – March 4, 2025 – Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. E |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| March 3, 2025 |
Exhibit 99.1 Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, March 03, 2025 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive inte |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| February 18, 2025 |
Enlivex Issues Urgent Statement on Fraudulent News Dissemination Exhibit 99.1 Enlivex Issues Urgent Statement on Fraudulent News Dissemination Ness-Ziona, Israel, Feb. 18, 2025 — Enlivex Therapeutics Ltd. (Nasdaq and TASE: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, alerts investors and the public that a completely false and misleading report regarding the Company was intentionally published this morning by the website |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2025 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| December 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| December 11, 2024 |
Exhibit 99.1 Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis Ness-Ziona, Israel, December 11, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health authorized the init |
|
| December 3, 2024 |
Exhibit 99.1 Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 29, 2024 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2024 AND 2023 IND |
|
| November 29, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| November 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 20, 2024 |
Enlivex Adopts Bitcoin Treasury Reserve Strategy Exhibit 99.1 Enlivex Adopts Bitcoin Treasury Reserve Strategy Nes-Ziona, Israel, November 20, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company’s Board of Directors approved the purchase of up to $1 million of Bitcoin as part of its cash management strategy. “As demand f |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 14, 2024 |
Exhibit 99.1 Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis Nes-Ziona, Israel, November 14, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the completion of the dosing and initial follow-up period |
|
| November 14, 2024 |
ENLV / Enlivex Therapeutics Ltd. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-enlv093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Enlivex Therapeutics Ltd. (Name of Issuer) Ordinary Shares, par value NIS 0.40 per share (Title of Class of Securities) M4130Y106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 12, 2024 |
Exhibit 99.1 Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the enrollment an |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| October 30, 2024 |
Exhibit 99.1 Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis Nes-Ziona, Israel, October 30, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Japanese Patent Office issued a notice of allowance f |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| October 15, 2024 |
Exhibit 99.1 Enlivex Therapeutics Ltd. (the “Company”) Amended and Restated Compensation Policy for Company Office Holders 1. The Objective of the Document The objective of this compensation policy (the “Policy”) is to define and describe the Company’s Office Holder compensation policy as required by the Israeli Companies Law – 1999 the “Companies Law”). It is emphasized that this Policy does not |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A (Amendment No. 1) Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Addr |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 26, 2024 |
Exhibit 99.1 Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Sept. 26, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the |
|
| September 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 24, 2024 |
Exhibit 99.1 Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data |
|
| September 11, 2024 |
Exhibit 99.2 THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN. EXCEPT AS MENTIONED OTHERWISE IN THE PROXY STATEMENT AND BELOW ON THIS PROXY, IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” THE PROPOSALS HEREIN. Please mark your vote as in this example PROPOSAL NO. 1: To elect the following persons to the Board of Directors, each to serve until the next annual general |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 11, 2024 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 31, 2024 Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Enlivex Therapeutics Ltd. (the “Company”), to be held on Thursday, October 31, 2024, at 7:00 p.m. (Israel time), at the offices of the Company at 14 Einstein Street, N |
|
| August 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exec |
|
| August 30, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| August 30, 2024 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2024 AND 2023 INDEX TO CONDENSED CONSOL |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| July 23, 2024 |
Exhibit 99.1 Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis ● First study of AllocetraTM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis1, and has limited treatment options Nes-Ziona, Israel, Ju |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 24, 2024 |
Exhibit 99.1 Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis · First patient dosed with AllocetraTM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people · Thumb osteoarthritis currently has no FDA-approved therapy and |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 20, 2024 |
Exhibit 99.1 Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25 Ness-Ziona, Israel, June 20, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on June 25, 2024, at 4:15 p.m. ET. The event, hos |
|
| June 17, 2024 |
Figure 1: Reduction in average pain, reported by patients Exhibit 99.1 Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis Key Highlights ● Enrolled patients with severe knee osteoarthritis who were indicated for knee-replacement surgery received a single local injection of AllocetraTM into the knee as a “last resort” ● Three-month data readout showed a significant reduction in pai |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 14, 2024 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| June 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 14, 2024 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 INDEX TO CONDENSED CONSOLIDATED FINAN |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 3, 2024 |
Exhibit 99.1 Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis ● First study of AllocetraTM in thumb osteoarthritis, a debilitating disease that affects millions of people in the U.S., and has no FDA-approved therapy ● Third study of AllocetraTM in osteoarthritis, following the o |
|
| May 29, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-264561 Prospectus Supplement to Prospectus dated May 5, 2022 ENLIVEX THERAPEUTICS LTD. 2,060,000 Ordinary Shares Pre-Funded Warrants to Purchase Up to 1,511,429 Ordinary Shares Series A Investor Warrants to Purchase Up to 3,571,429 Ordinary Shares Series B Investor Warrants to Purchase Up to 3,571,429 Ordinary Shares Series A Placement Agent Wa |
|
| May 29, 2024 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.3 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: Issue Date:, 2024 Initial Exercise Date: , 2024 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time |
|
| May 29, 2024 |
SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.5 SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: Issue Date: May 29, 2024 Initial Exercise Date: May 29, 2024 THIS SERIES B PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi |
|
| May 29, 2024 |
SERIES A PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.4 SERIES A PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: Issue Date: May 29, 2024 Initial Exercise Date: May 29, 2024 THIS SERIES A PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the condi |
|
| May 29, 2024 |
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering Exhibit 99.1 Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering Nes-Ziona, Israel, May 29, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of a |
|
| May 29, 2024 |
SERIES A ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.1 SERIES A ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: Issue Date: May 29, 2024 Initial Exercise Date: May 29, 2024 THIS SERIES A ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executi |
|
| May 29, 2024 |
SERIES B ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Exhibit 4.2 SERIES B ORDINARY SHARE PURCHASE WARRANT Enlivex Therapeutics Ltd. Warrant Shares: Issue Date: May 29, 2024 Initial Exercise Date: May 29, 2024 THIS SERIES B ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| May 29, 2024 |
Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 27, 2024, between Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, s |
|
| May 28, 2024 |
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering Exhibit 99.1 Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering ● Single healthcare-focused institutional investor ● $5 million upfront with up to an additional $10 million of gross proceeds upon the exercise in full of clinical milestone-linked warrants Nes-Ziona, Israel, May 28, 2024 (GLOBE NEWSWIRE) – Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-s |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executi |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2024 |
DESCRIPTION OF ORDINARY SHARES Exhibit 2.1 DESCRIPTION OF ORDINARY SHARES As of the end of the period covered by the most recent Annual Report on Form 20-F of Enlivex Therapeutics Ltd. (the “Company”) to which this Exhibit is filed, or incorporated by reference, as an exhibit, the Company’s ordinary shares, with a par value of NIS 0.40 per share (the “ordinary shares”), were registered under Section 12 of the Securities Exchang |
|
| April 30, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2023 (the “Report”) by Enlivex Therapeutics Ltd. (the “Company”), the undersigned, as the Chief Financial Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley |
|
| April 30, 2024 |
Enlivex Therapeutics Ltd. Executive Officer Clawback Policy Exhibit 97.1 Enlivex Therapeutics Ltd. Executive Officer Clawback Policy Approved by the Board of Directors on November 28, 2023 (the “Adoption Date”) I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, and any of its direct or indirect subsidiaries (collec |
|
| April 30, 2024 |
Exhibit 4.18 AGREEMENT This Agreement ( “Agreement”), made effective as of 31th of Marc, 2024 (“Effective Date”), is entered into by and between BioHarvest Ltd., an Israeli company, having an address at 3th Pekeris St. Rehovot (“BioHarvest”), and Enlivex Therapeutics R&D, Ltd., an Israeli company having an address at EINSTEIN 14TH St, NESS ZIONA (“Enlivex”). WHEREAS, Enlivex is the lessee of a pro |
|
| April 30, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.1 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Dr. Oren Hershkovitz, certify that: 1. I have reviewed this Annual Report on Form 20-F of Enlivex Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances und |
|
| April 30, 2024 |
CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) Exhibit 12.2 CERTIFICATION PURSUANT TO EXCHANGE ACT RULE 13a-14(a) or 15d-14(a) I, Shachar Shlosberger, certify that: 1. I have reviewed this Annual Report on Form 20–F of Enlivex Therapeutics Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances unde |
|
| April 30, 2024 |
Exhibit 1.1 Articles of Association of Enlivex Therapeutics Ltd. A Company Limited by Shares Under The Companies Law, 5759-1999 Chapter 1 General 2 Chapter 2 Shares and Share Capital 3 Chapter 3 General Meetings 7 Chapter 4 The Board of Directors 11 Chapter 5 Committees of the Board of Directors 15 Chapter 6 General Manager 16 Chapter 7 Exemption, Insurance, and Indemnification 16 Chapter 8 Intern |
|
| April 30, 2024 |
CONSENT OF INDEPENDENT ACCOUNTANTS Exhibit 15.1 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-264561) of Enlivex Therapeutics Ltd. of our report dated March 25, 2024 with respect to the consolidated financial statements and the effect |
|
| April 30, 2024 |
CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. Section 1350 In connection with the filing of the Annual Report on Form 20–F for the period ended December 31, 2023 (the “Report”) by Enlivex Therapeutics Ltd. (the “Company”), the undersigned, as the Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley |
|
| April 29, 2024 |
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events Exhibit 99.1 Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events Nes-Ziona, Israel, April 29, 2024 (GLOBE NEWSWIRE) – Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today issued the following update to shareholders from Chief Executive Officer, Oren Hershkovitz. Dear fellow shareholders, I |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| April 22, 2024 |
Exhibit 99.1 Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis Nes-Ziona, Israel, April 22, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first two patients have been dosed |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| April 16, 2024 |
Exhibit 99.1 Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danis |
|
| April 11, 2024 |
Exhibit 99.2 Nasdaq: ENLV COMPANY PRESENTATION April 2024 2 | Nasdaq: ENLV FORWARD - LOOKING STATEMENTS These slides and the accompanying oral presentation contain forward - looking statements and information. Forward - looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or |
|
| April 11, 2024 |
Exhibit 99.1 Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis ● Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) ■ In accordance with the study protocol, the safety and efficacy topline analysis includes sequential organ failure assessment (SOFA) scores and mortality for the 28-day period post treatment. ■ Efficac |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| March 29, 2024 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 ENLIVEX THERAPEUTICS LTD. FINANCIAL STATEMENTS AS OF DECEMBER 31, 2023 INDEX Page Report of Independent Registered Public Accounting Firm F-2 Consolidated Balance Sheets F-5 Consolidated Statements of Operations and Comprehensive Loss F-6 Consolidated Statements of Changes in Shareholders’ Equity F-7 Consolidated S |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: March 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| March 29, 2024 |
CONSENT OF INDEPENDENT ACCOUNTANTS Exhibit 99.2 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Forms S-8, F-3 and F-3MEF (File No. 333-256799, File No. 333-232413, File No. 333-232009, File No. 333-252926 and File No. 333-264561) of Enlivex Therapeutics Ltd. of our report dated March 25, 2024 with respect to the consolidated financial statements and the effect |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: February 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| February 7, 2024 |
Exhibit 99.1 Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method Nes-Ziona, Israel, Feb. 07, 2024 (GLOBE NEWSWIRE) – Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a new patent, number US 11,883,429, covering |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| January 17, 2024 |
Exhibit 99.1 Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis ● Second study of Allocetra in knee osteoarthritis, following the on-going Phase I/II trial in pre-surgery, end-stage osteoarthritis, that is continuing to enroll patients Ne |
|
| January 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: January 2024 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| December 20, 2023 |
Exhibit 99.1 Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis · Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis study · Topline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 19, 2023 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clin |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: December 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 9, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 9, 2023 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 IND |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: November 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal ex |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: October 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exe |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Ness Ziona, Israel 7403618 (Address of principal |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 13, 2023 |
Exhibit 99.2 THIS PROXY WHEN PROPERLY EXECUTED WILL BE VOTED AS DIRECTED HEREIN. EXCEPT AS MENTIONED OTHERWISE IN THE PROXY STATEMENT AND BELOW ON THIS PROXY, IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” THE PROPOSALS HEREIN. Please mark your vote as in this example ☒ PROPOSAL NO. 1: To elect the following persons to the Board of Directors, each to serve until the next annual gener |
|
| September 13, 2023 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To be held on October 26, 2023 Dear Shareholder: We cordially invite you to attend the Annual General Meeting of Shareholders (the “Meeting”) of Enlivex Therapeutics Ltd. (the “Company”), to be held on Thursday, October 26, 2023, at 7:00 p.m. (Israel time), at the offices of the Company at 14 Einstein Street, N |
|
| September 11, 2023 |
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results Exhibit 99.1 Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results ● The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of AllocetraTM as an innovative, highly-differentiated modality for immune resolution across a wide variety of inflammatory and auto-immune |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| September 1, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| September 1, 2023 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND SIX MONTH PERIODS ENDED JUNE 30, 2023 AND 2022 INDEX TO CONDENSED CONSOL |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: September 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal e |
|
| August 2, 2023 |
Exhibit 99.1 Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevat |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: August 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal exec |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: July 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| July 31, 2023 |
Exhibit 99.1 Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis Nes-Ziona, Israel, Jul 31, 2023 (GLOBE NEWSWIRE) – Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the first patient has been dosed under the amended proto |
|
| June 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 26, 2023 |
Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update Exhibit 99.1 Enlivex Announces First Quarter 2023 Financial Results and Provides a Business Update ● Enrollment of patients in the Phase I/II evaluating Allocetra™ in combination with chemotherapy in patients with peritoneal metastases from advanced solid tumors is proceeding as planned, with 50% (lower dose cohorts) already enrolled. ● The integration of tislelizumab, an anti-PD-1 immune checkpoi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: June 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execut |
|
| June 16, 2023 |
Exhibit 99.1 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2023 AND 2022 INDEX TO CONSOLIDATED FINANCIAL STATE |
|
| June 16, 2023 |
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Exhibit 99.2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS This Operating and Financial Review and Prospects contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could”, “intends,” “estimates,” “suggests,” “has the potential to” and other words and phrases of similar meaning, inclu |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executi |
|
| May 31, 2023 |
Exhibit 99.1 Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy Nes-Ziona, Israel, May 31, 2023 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today annou |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: May 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal executi |
|
| May 8, 2023 |
Exhibit 99.1 Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy Nes-Ziona, Israel, May 08, 2023 (GLOBE NEWSWIRE) – Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of a European patent, numbered |
|
| April 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of: April 2023 Commission file number: 001-36578 ENLIVEX THERAPEUTICS LTD. (Translation of registrant’s name into English) 14 Einstein Street, Nes Ziona, Israel 7403618 (Address of principal execu |
|
| April 19, 2023 |
Exhibit 99.1 Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy Nes-Ziona, Israel, April 19, 2023 (GLOBE NEWSWIRE) - Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages, today announced that the U.S. Patent and Tra |
